Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aripiprazole + quetiapine
- Development stage
- Phase 4
- Lead developer
- Otsuka Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of two atypical antipsychotic medications. Aripiprazole acts as a partial agonist at dopamine and serotonin receptors, while quetiapine functions as an antagonist at these receptors. This combination is generally considered pharmacologically irrational due to overlapping effects and increased risk of side effects.
02
Targets
ADRA1A (α1A)ADRA2A (α2A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on aripiprazole + quetiapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aripiprazole + quetiapine.